Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-739-6 | CAS number: 68606-29-1 A complex combination of hydrocarbons produced during butylene concentrate production. It consists predominantly of C4 and C8 hydrocarbons.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There is a 28 day repeat oral dosing study with triisobutylene with 14 day recovery. There are also repeat dose toxicity studies with other higher olefins spanning the range C8 to C20. The data for these studies indicate that the location of the double bond or the addition of branching to the structure do not appear to affect the toxicity. Higher olefins are of low toxicity in rats. Male rat kidney effects indicative of alpha-2u-globulin nephropathy consistently occur with the C8 to C14 higher olefins. Alpha-2u-globulin nephropathy is considered to be male rat-specific and is not relevant for humans. Treatment-related liver effects (increased organ weights, hepatocyte cytoplasmic vacuolation, and centrilobular hepatocyte hypertrophy) are also observed in rats exposed to higher olefins, which may reflect adaptive changes as a result of the high liver burden of these substances. There is no evidence of neurotoxicity.
Key value for chemical safety assessment
Additional information
The remaining higher olefins have been tested in oral gavage studies. In a 28-day oral study, male and female CD rats were given by gavage 0, 100, 300 or 1000 mg/kg 2,4,4-trimethylpentene (HLS, 1997 b). Compared to controls, kidney weights were increased in the 1000 mg/kg males and liver weights were increased in the 1000 mg/kg males and females. No adverse histopathological effects were noted. The NOAEL was 300 mg/kg-day. In an OECD 421 study, male and female CD rats were dosed by oral gavage with 0, 100, 300 or 1,000 mg/kg (HLS, 1997 c). Males received 44 to 46 doses and females received 40-45 doses. Liver and kidney weights were increased in both males (300 and 1,000 mg/kg) and females (1,000 mg/kg) compared to controls. Histopathological effects, however, were observed only in the kidneys of all treated male rats, and consisted of basophilic cortical tubules and proteinaceous casts and interstitial cells (300 and 1,000 mg/kg groups only). The kidney effects were further investigated in a special study (Shell, 2004) and concluded to bemale rat-specific kidney effects indicative of alpha-2u-globulin nephropathy which are considered not to be relevant to humans. The NOAEL for this study is 300 mg/kg.
In a 28 day study with triisobutylene (CAS 7756 -94 -7, Biosafety Research Centre Japan) there were no treatment related clinical signs and no effects on body weight or food consumption at doses up to 750 mg/kg/day. Small decreases inred blood cell counts were seen in females of the 150 and 750mg/kg bw/daygroups, and the prothrombin time was slightly shorter than control in females of the 750mg/kg bw/daygroup. Histopathological examination revealed swelling of liver cells in both sexes of the 150 and 750 mg/kg bw/day groups, and eosinophilic bodies in renal tubules in males of the 150 and 750 mg/kg groups. These changes were accompanied by increases in absolute and relative liver weights in both sexes at 750 mg/kg bw/day and in males at 150 mg/kg bw/ day. Absolute or relative kidney weights were increased in males of the 150 and 750 mg/kg groups but not in females. Absolute and relative spleen weights were decreased in females of the 750 mg/kg group. A systemic toxicity NOEL of 30 mg/kg/day was established based on, haematology, organ weight, and histopathology changes in the liver and kidneys at a dose level of 150 mg/kg bw/day. In animals dosed with for 28 days and then maintained for a 14 day recovery period the only finding was basophilic change in the kidneys of both sexes.
1-Tetradecene (CAS 1120 -36 -1, a C16 olefin) was administered by oral gavage to rats at doses of 0, 100, 500 or 1000 mg/kg/day in corn oil in an OECD 422 study (Springborn laboratories, 1995). The males and an unbred satellite group of females were dosed for 28 days prior to mating and until euthanasia (43-47 days of dosing). Breeding females were dosed for 14 days prior to mating, during mating, gestation, and lactation until euthanasia (42-51 days of dosing). Increased liver weights and minimal-to-moderate hepatocyte cytoplasmic vacuolation were observed in the 500 and 1000 mg/kg animals; and increased hyaline droplets in the proximal convoluted tubules only in male rats at all doses. The male rat hydrocarbon nephropathy was concluded to be unique to the male rat, and not suggestive of an adverse effect for human risk assessment.
In an OECD 421 study, male and female rats were dosed with 0, 100, 500 or 1000 mg/kg C18 branched and linear olefins (CAS 27070 -58 -2 and CAS 18236 -02 -8) for approximately 6 weeks (Springborn Laboratories, 2003). There were no treatment-related effects. The NOAEL was 1000 mg/kg-day.
C20-24 branched and linear olefins were given by oral gavage to male and female rats for 13 weeks at doses of 0, 100, 500 or 1,000 mg/kg (HLS, 1999). An additional group of male and female rats were dosed with either 0 or 1000 mg/kg test material for 13 weeks followed by a 4-week recovery period. In treated females, liver weights were significantly increased, which was associated with centrilobular hepatocyte hypertrophy (statistically significant only in the 1000 mg/kg group. Adrenal weights were also significantly increased in all treated females, with a statistically significant increased incidence of minimal or slight adrenal cortical hypertrophy in the 1000 mg/kg females compared with controls.
Several of these repeat dose studies have neurotoxicity screening assessments in the repeat dose toxicity studies (isooctene, 2,4,4-trimethylpentene, C14 alpha olefin, and C20-24 linear/branched internal olefins). No treatment-related effects were observed.
Human data
No human information is available.
Justification for classification or non-classification
There are sufficient data available on olefins from C8 to C18 to conclude that the butylenes oligomers are of low repeat dose toxicity by the oral and inhalation routes with no indication of serious functional or morphological effects. Classification is not warranted for butylene oligomers under Dir 67/548/EEC or GHS/CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.